Nycomed is a Takeda company since October 2011. Takeda is a research-based global company with its main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
Takeda’s traditional strengths in North America, Japan, and the rest of Asia, are now complemented by Nycomed’s position in Europe and the high growth emerging markets. It is present in more than 70 countries worldwide, and ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe.
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better
health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Our Mission
We bring medicines that matter to patients and healthcare providers.
Our Vision
We strive for excellence in all we do to improve the quality of life for patients around the world.
Business results and main therapeutic areas
In 2010, total net turnover reached €3.2 billion, with an adjusted EBITDA of €851 million. Nycomed ranks 28th among global pharmaceutical companies.
Nycomed offers a diversified product range focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.
Global R&D and Manufacturing presence
Research and Development is conducted at three sites in Europe and one in India. New products are sourced from our own internal Discovery organisation and in-licensed from external companies such as small biotechs. Establishing long-term partnerships is a cornerstone of Nycomed´s growth strategy.
Nycomed has 15 manufacturing sites: 5 centres of competence in Europe for global products as well as 10 production sites for regional products in fast-growing countries such as Brazil and Mexico. A major investment is being made in a new pharmaceutical plant in Russia, currently Nycomed’s biggest single market.